SavedAdd your journal

Journals / Astım Allerji İmmünoloji / 2015 / Cilt: 13 - Sayı: 3

L-asparajinaz ile gelişen cilt reaksiyonları: Allerji mi, infeksiyon mu?

Adverse skin reactions caused by L-asparaginase: dverse skin reactions caused by L-asparaginase: Allergy or infection?

Ayşenur BAHADIR
Pınar GÖKÇE REİS
Erol ERDURAN
Fazıl ORHAN
Mehtap HAKTANIR ABUL
Pages
130–133
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

All of the patients were treated with pegylated E. coli asparaginase, and none reported complaints during the follow-up.Conclusion: Th e local reactions in these cases were regarded as allergic due to the recurrence upon challenge and the recovery aft er diff erent drugs were prescribed; and these reactions occurred particularly in the low-risk group who were receiving the drug every other day in re-induction I

📌 3 Key Takeaways

🎯
Objective & Hypothesis:L-asparaginase (L-ASP) is one of the indispensible medications used in the treatment of acute lymphoblastic leukemia (ALL); however, the allergic reactions caused by the drug limit its use. 52 patients (37 were low risk, 15 were high risk) who were followed for ALL between January 2010 and July 2014 and who developed local and systemic reactions associated with Escherichia coli L-ASP were evaluated.Results: Of the 52 patients with ALL who underwent therapy according to the St Jude Total XV chemotherapy protocol, three patients developed systemic allergic reaction (anaphylaxis) and eight developed swelling, erythema and increased skin temperatures at the injection site and as well as systemic fever (> 38°C) aft er E. coli L-ASP therapy.
📊
Key Findings & Data:L-asparaginase (L-ASP) is one of the indispensible medications used in the treatment of acute lymphoblastic leukemia (ALL); however, the allergic reactions caused by the drug limit its use. 52 patients (37 were low risk, 15 were high risk) who were followed for ALL between January 2010 and July 2014 and who developed local and systemic reactions associated with Escherichia coli L-ASP were evaluated.Results: Of the 52 patients with ALL who underwent therapy according to the St Jude Total XV chemotherapy protocol, three patients developed systemic allergic reaction (anaphylaxis) and eight developed swelling, erythema and increased skin temperatures at the injection site and as well as systemic fever (> 38°C) aft er E. coli L-ASP therapy.
💡
Conclusion & Impact:All of the patients were treated with pegylated E. coli asparaginase, and none reported complaints during the follow-up.Conclusion: Th e local reactions in these cases were regarded as allergic due to the recurrence upon challenge and the recovery aft er diff erent drugs were prescribed; and these reactions occurred particularly in the low-risk group who were receiving the drug every other day in re-induction I
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

L-asparaginase (L-ASP) is one of the indispensible medications used in the treatment of acute lymphoblastic leukemia (ALL); however, the allergic reactions caused by the drug limit its use. 52 patients (37 were low risk, 15 were high risk) who were followed for ALL between January 2010 and July 2014 and who developed local and systemic reactions associated with Escherichia coli L-ASP were evaluated.Results: Of the 52 patients with ALL who underwent therapy according to the St Jude Total XV chemotherapy protocol, three patients developed systemic allergic reaction (anaphylaxis) and eight developed swelling, erythema and increased skin temperatures at the injection site and as well as systemic fever (> 38°C) aft er E. coli L-ASP therapy. All of the patients were treated with pegylated E. coli asparaginase, and none reported complaints during the follow-up.Conclusion: Th e local reactions in these cases were regarded as allergic due to the recurrence upon challenge and the recovery aft er diff erent drugs were prescribed; and these reactions occurred particularly in the low-risk group who were receiving the drug every other day in re-induction I

Özet

L-asparajinaz akut lenfoblastik lösemi (ALL) tedavisinde kullanılan vazgeçilemez ilaçlardandır fakat ilaca bağlı allerjik reaksiyonlar bu ilacın kullanılmasını kısıtlamaktadır. Ocak 2010 ile Temmuz 2014 tarihleri arasında ALL sebebiyle takip edilen 52 hasta (37'si düşük risk ALL, 15'i yüksek risk ALL) çalışmaya alındı ve Escherichia coli L-ASP'a bağlı gelişen lokal ya da sistemik reaksiyonlar açısından değerlendirildi.Bulgular: ALL tanısıyla takip edilen ve St. Jude Total XV kemoterapi protokolü alan 52 hastada E. coli L-ASP uygulanımı sonrasında üçünde sistemik allerjik reaksiyon (anafilaksi) gelişirken, sekiz hastada enjeksiyon bölgesinde şişlik, kızarıklık, lokal ısı artışı ve sistemik ateş (> 38°C) gözlendi. Hastaların tedavisine pegylated- E. coli L-ASP ile devam edildi ve hastaların takibinde ilaca bağlı reaksiyon gözlenmedi.Sonuç: Hastadaki lokal reaksiyonların ilacın tekrar uygulamaları ile yenilemesi fakat farklı bir ilaca geçildikten sonra gözlenmemesi öncelikle ilaca bağlı allerjik reaksiyonu düşündürdü. Bu reaksiyonlar özellikle düşük risk ALL tanısıyla takip edilen, re-indüksiyon I tedavi protokolünde ilacı gün aşırı alan hastalarda daha sıklıkla görülmektedir

🔖

Cite This Article

BAHADIR, A., REİS, P. G., ERDURAN, E., ORHAN, F., ABUL, M. H. (2015). L-asparajinaz ile gelişen cilt reaksiyonları: Allerji mi, infeksiyon mu?. Astım Allerji İmmünoloji, Cilt: 13 - Sayı: 3, 130–133. https://ajindex.com/articles/150450

References (10)

  1. Cremer P, Lakomek M, Beck W, Prindull G. Th e eff ect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia. Eur J Pediatr 1988;147:64-7. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992;19:458-77.
  2. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315:657-63.
  3. Raetz EA, Salzer WL. Tolerability and effi cacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010;32:554-63.
  4. Shinnick SE, Browning ML, Koontz SE. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults. J Pediatr Oncol Nurs 2013;30:63-77.
  5. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525-32.
  6. Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012;26:2303-9. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010;105:259-73.
  7. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Critical reviews in oncology/hematology 2007;61:208-21.
  8. Soyer OU, Aytac S, Tuncer A, Cetin M, Yetgin S, Sekerel BE. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. J Allergy Clin Immunol 2009;123:895-9.
  9. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Critical reviews in oncology/hematology 1998;28:97-113.
  10. Fabry U, Korholz D, Jurgens H, Gobel U, Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-mediated mechanism. Pediatric Research 1985;19:400-8. Hay RJ. Preventing cellulitis: where next? Br J Dermatol 2014;171:1304-6.